Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial

INTRODUCTION: Persons with type 1 diabetes require intensive insulin therapy to achieve glycaemic control, but side effects, including hypoglycaemia and weight gain, may reduce treatment compliance. We hypothesise that add-on treatment of the short-acting glucagon-like peptide-1 receptor agonist, ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansen, Nicklas Järvelä, Dejgaard, Thomas Fremming, Lund, Asger, Vilsbøll, Tina, Andersen, Henrik Ullits, Knop, Filip Krag
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042609/
https://www.ncbi.nlm.nih.gov/pubmed/29950475
http://dx.doi.org/10.1136/bmjopen-2018-021861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042609/
https://www.ncbi.nlm.nih.gov/pubmed/29950475
http://dx.doi.org/10.1136/bmjopen-2018-021861

Ejemplares similares